Ropes & Gray Represents EQRx in Drug Collaboration with Aurigene
Ropes & Gray represented EQRx in a strategic drug creation, development, and commercialization collaboration with Aurigene Discovery Technologies Limited to develop drug candidates targeting oncology and immune-inflammatory diseases utilizing Aurigene’s small molecule drug discovery platform. The transaction was announced on July 5 and financial terms were not disclosed. India and Malaysia-based Aurigene is a wholly owned subsidiary of Dr. Reddy’s Laboratories.
Under the agreement, Aurigene will lead drug discovery and pre-clinical development. EQRx will assume responsibility for clinical development, manufacturing, regulatory and commercialization efforts. The parties will share costs for the discovery and development of, as well as profits resulting from the commercialization of, any future drug candidates.
The Ropes & Gray team was led by life sciences partner Abigail Gregor and included life sciences associate Jesse Lamas.